The Peptide Wiki
Mapping Knowledge.
Advancing Discovery.
📩 Subscribe
// STATE LEGISLATION TRACKER

New Mexico SB 477: NO PRIOR AUTHORIZATION FOR CERTAIN DRUGS

⚖️ MIXED for peptide users 👤 NONE user impact 📜 Status: Failed
State
New Mexico
Bill
SB 477
Session
2025
Filed
2025-02-20
Read the bill
OpenStates →
Last reviewed
2026-10-02

Plain-English Summary

SB477 would have limited prior authorization or step therapy for certain FDA-approved prescription drugs, including GLP-1/GIP drug classes. It appears relevant to FDA-approved metabolic peptide drugs, but not to compounded peptides, 503A/503B compounding rules, telehealth prescribing, NP or naturopathic scope, controlled substances, or prescription monitoring.

Key Points

  • No current change for peptide patients because the bill died
  • Would have helped access to FDA-approved GLP-1/GIP drugs
  • Does not appear to protect compounded peptide access
  • Does not expand telehealth prescribing or clinician scope
  • Does not address controlled substances or PDMP rules

What to Watch For

✓
Opportunity A future version could reduce insurance delays for FDA-approved GLP-1/GIP medications.
!
Concern Compounded peptides would likely remain outside the bill unless future text names compounding or non-FDA-approved products.
i
Note The bill was postponed indefinitely, so it should be treated as inactive for 2025.

Where the Bill Stands

The New Mexico Legislature lists SB477 as died after action was postponed indefinitely on February 20, 2025.
· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.
Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws